

Pacira Pharmaceuticals, Inc.
 Form 4
 June 14, 2013

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Pratt John

(Last) (First) (Middle)

C/O PACIRA
 PHARMACEUTICALS,
 INC., 10450 SCIENCE CENTER
 DRIVE

(Street)

SAN DIEGO, CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pacira Pharmaceuticals, Inc. [PCRX]

3. Date of Earliest Transaction
 (Month/Day/Year)
06/12/2013

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director ___ 10% Owner
 Officer (give title below) ___ Other (specify below)
General Manager, San Diego

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/12/2013		M		925	A	\$ 10.81
Common Stock	06/12/2013		S		925	D	\$ 30
Common Stock	06/13/2013		M		18,232	A	\$ 10.81
Common Stock	06/13/2013		S		18,232	D	\$ 30
	06/13/2013		M		1,875	A	\$ 8.73

Common Stock

Common Stock 06/13/2013 S 1,875 D \$ 30 0 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares	
						Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 10.81	06/12/2013		M	925	<u>(1)</u> 06/04/2022	Common Stock	925	
Employee Stock Option (right to buy)	\$ 10.81	06/13/2013		M	18,232	<u>(1)</u> 06/04/2022	Common Stock	18,232	
Employee Stock Option (right to buy)	\$ 8.73	06/13/2013		M	1,875	<u>(2)</u> 01/02/2022	Common Stock	1,875	

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Pratt John
C/O PACIRA PHARMACEUTICALS, INC.

General Manager, San Diego

10450 SCIENCE CENTER DRIVE
SAN DIEGO, CA 92121

Signatures

/s/ John Pratt

06/14/2013

__Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vests and becomes exercisable as to the remaining shares in successive equal monthly installments for the subsequent 36 months.
- (2) The option vested and became exercisable as to 25% of the option shares on January 3, 2013 and vests and becomes exercisable as to the remaining shares in successive equal monthly installments at the end of each month over the subsequent 36 months.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.